339 related articles for article (PubMed ID: 23576565)
1. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.
Simon S; Grabellus F; Ferrera L; Galietta L; Schwindenhammer B; Mühlenberg T; Taeger G; Eilers G; Treckmann J; Breitenbuecher F; Schuler M; Taguchi T; Fletcher JA; Bauer S
Cancer Res; 2013 Jun; 73(12):3661-70. PubMed ID: 23576565
[TBL] [Abstract][Full Text] [Related]
2. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
3. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
Bardsley MR; Horváth VJ; Asuzu DT; Lorincz A; Redelman D; Hayashi Y; Popko LN; Young DL; Lomberk GA; Urrutia RA; Farrugia G; Rubin BP; Ordog T
Gastroenterology; 2010 Sep; 139(3):942-52. PubMed ID: 20621681
[TBL] [Abstract][Full Text] [Related]
4. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.
Mahadevan D; Cooke L; Riley C; Swart R; Simons B; Della Croce K; Wisner L; Iorio M; Shakalya K; Garewal H; Nagle R; Bearss D
Oncogene; 2007 Jun; 26(27):3909-19. PubMed ID: 17325667
[TBL] [Abstract][Full Text] [Related]
5. PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1.
Baskin Y; Kocal GC; Kucukzeybek BB; Akbarpour M; Kayacik N; Sagol O; Ellidokuz H; Oztop I
Oncol Res; 2016; 24(1):41-53. PubMed ID: 27178821
[TBL] [Abstract][Full Text] [Related]
6. Functional role of the Ca²⁺-activated Cl⁻ channel DOG1/TMEM16A in gastrointestinal stromal tumor cells.
Berglund E; Akcakaya P; Berglund D; Karlsson F; Vukojević V; Lee L; Bogdanović D; Lui WO; Larsson C; Zedenius J; Fröbom R; Bränström R
Exp Cell Res; 2014 Aug; 326(2):315-25. PubMed ID: 24825187
[TBL] [Abstract][Full Text] [Related]
7. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
9. Familial gastrointestinal stromal tumor syndrome: report of 2 cases with KIT exon 11 mutation.
Jones DH; Caracciolo JT; Hodul PJ; Strosberg JR; Coppola D; Bui MM
Cancer Control; 2015 Jan; 22(1):102-8. PubMed ID: 25504284
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Tang CM; Lee TE; Syed SA; Burgoyne AM; Leonard SY; Gao F; Chan JC; Shi E; Chmielecki J; Morosini D; Wang K; Ross JS; Kendrick ML; Bardsley MR; Siena M; Mao J; Harismendy O; Ordog T; Sicklick JK
Oncotarget; 2016 Nov; 7(48):78226-78241. PubMed ID: 27793025
[TBL] [Abstract][Full Text] [Related]
11. [Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts].
Zheng S; Wang XJ; Jia J; Pan YL; Tao DY; Lu HS; Huang KE
Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):176-80. PubMed ID: 22800481
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
13. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
Hemming ML; Lawlor MA; Andersen JL; Hagan T; Chipashvili O; Scott TG; Raut CP; Sicinska E; Armstrong SA; Demetri GD; Bradner JE
Cancer Res; 2019 Mar; 79(5):994-1009. PubMed ID: 30630822
[TBL] [Abstract][Full Text] [Related]
14. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
Zook P; Pathak HB; Belinsky MG; Gersz L; Devarajan K; Zhou Y; Godwin AK; von Mehren M; Rink L
Clin Cancer Res; 2017 Jan; 23(1):171-180. PubMed ID: 27370604
[TBL] [Abstract][Full Text] [Related]
15. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
[TBL] [Abstract][Full Text] [Related]
16. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
Edris B; Willingham SB; Weiskopf K; Volkmer AK; Volkmer JP; Mühlenberg T; Montgomery KD; Contreras-Trujillo H; Czechowicz A; Fletcher JA; West RB; Weissman IL; van de Rijn M
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3501-6. PubMed ID: 23382202
[TBL] [Abstract][Full Text] [Related]
17. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
[TBL] [Abstract][Full Text] [Related]
18. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
Weisberg E; Wright RD; Jiang J; Ray A; Moreno D; Manley PW; Fabbro D; Hall-Meyers E; Catley L; Podar K; Kung AL; Griffin JD
Gastroenterology; 2006 Dec; 131(6):1734-42. PubMed ID: 17087936
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
Gebreyohannes YK; Schöffski P; Van Looy T; Wellens J; Vreys L; Cornillie J; Vanleeuw U; Aftab DT; Debiec-Rychter M; Sciot R; Wozniak A
Mol Cancer Ther; 2016 Dec; 15(12):2845-2852. PubMed ID: 27777285
[TBL] [Abstract][Full Text] [Related]
20. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
